CompletedNot Applicable

The Effect of Solifenacin on Post Void Dribbling in Women

United States118 participantsStarted 2011-11

Plain-language summary

This is a double-blind, randomized, controlled, parallel design (n=140) study with the purpose of measuring the efficacy of Solifenacin 5mg in the treatment of women with Post Void Dribbling.

Who can participate

Age range18 Years – 89 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Women between the ages of 18 and 89
✓. Incontinence in the form of post void dribbling that occurs at least twice weekly.

Exclusion criteria

✕. Severe renal or hepatic disease.
✕. Active urinary tract infection.
✕. Glaucoma.
✕. Stress incontinence as the only incontinence symptom
✕. Urge incontinence as the only incontinence symptom
✕. Chronic severe constipation.
✕. History of bladder cancer.
✕. Known or suspected hypersensitivity to anticholinergics.

What they're measuring

The Percent Reduction in Post Void Dribbling Episodes (Events)

Timeframe: outcome measures will be assessed at week 0 (baseline), and compared to an average measure of weeks 10 through 12

Trial details

NCT IDNCT01470001

SponsorUniversity of Wisconsin, Madison

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-09

Results submitted2016-09-28

View on ClinicalTrials.gov More Post-micturition Incontinence trials